Safety and efficacy of natalizumab in children with multiple sclerosisAngelo Ghezzi, Gıancarlo Comı, Paola Sarchielli et al.|Neurology|2010Cited by 93
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Giancarlo Di Battista, Pietro Annovazzi et al.|Journal of Neurology|2018Cited by 54
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study groupAntonio Bertolotto, Simona Malucchi, Marco Capobianco et al.|Neurological Sciences|2013Cited by 37
The pharmacovigilance program on natalizumab in Italy: 2 years of experienceG. Tedeschi, Gianluigi Mancardi, Maria Pia Amato et al.|Neurological Sciences|2009Cited by 13
Erratum to: Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study groupAntonio Bertolotto, Simona Malucchi, Marco Capobianco et al.|Neurological Sciences|2014Cited by 2